Spotlight On: Actemra® (Tocilizumab) / Tofidence™ (Tocilizumab-Bavi) / Tyenne® (Tocilizumab-Aazg) / Avtozma® (Tocilizumab-Anoh) - April 2026

Why It Matters

Accurate claim counting influences litigation risk, licensing value, and market exclusivity for high‑revenue biologics like tocilizumab, shaping biotech investors’ and companies’ strategic decisions.

Key Takeaways

• Claims counted per IPR can inflate perceived patent strength
• Duplicate claim counts arise when same patent faces multiple IPRs
• Strategy must consider cross‑IPR claim aggregation for biotech firms
• Accurate claim metrics affect licensing negotiations and valuation
• Tocilizumab portfolio faces heightened scrutiny under §102 and §103

Pulse Analysis

Inter Partes Review (IPR) has become a primary tool for challenging biotech patents, and the tocilizumab franchise illustrates the nuances of claim accounting. When a single patent is targeted in several IPRs, each proceeding tallies the same set of claims anew, creating an illusion of a larger claim portfolio. This double‑counting can mislead stakeholders about the breadth of protection, especially when claims are evaluated under both novelty (§102) and non‑obviousness (§103) standards. Understanding this counting methodology is essential for accurate patent valuation and risk assessment.

For companies that own or license tocilizumab products, the inflated claim count can affect licensing negotiations, royalty structures, and merger‑acquisition pricing. Investors scrutinize the number of enforceable claims as a proxy for market exclusivity; overstated figures may inflate expectations and lead to mispriced deals. Legal teams must therefore track claim overlap across IPRs, ensuring that any settlement or licensing offer reflects the true, non‑duplicated claim set. Precise metrics also guide defensive strategies, such as filing continuations or pursuing alternative patent families to shore up protection.

The broader industry takeaway is a call for heightened diligence in patent portfolio management. As the USPTO continues to grant IPRs at a brisk pace, biotech firms must adopt robust claim‑mapping tools and coordinate with counsel to avoid inadvertent double‑counting. Transparent reporting of claim counts not only supports regulatory compliance but also builds credibility with investors and partners. By aligning claim accounting with strategic business objectives, companies can better navigate the complex landscape of biologic patent litigation and maintain competitive advantage.